Xpress Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Xpress Biologics's estimated annual revenue is currently $10.4M per year.
- Xpress Biologics's estimated revenue per employee is $155,000
Employee Data
- Xpress Biologics has 67 Employees.
- Xpress Biologics grew their employee count by 37% last year.
Xpress Biologics's People
Name | Title | Email/Phone |
---|
Xpress Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.6M | 49 | 29% | N/A | N/A |
#2 | $19.8M | 128 | -14% | N/A | N/A |
#3 | $249.2M | 1608 | 5% | N/A | N/A |
#4 | $28.4M | 183 | -19% | N/A | N/A |
#5 | $7.1M | 46 | 5% | $30.5M | N/A |
#6 | $5M | 32 | -9% | N/A | N/A |
#7 | $16.6M | 107 | 45% | N/A | N/A |
#8 | $6.7M | 43 | 48% | N/A | N/A |
#9 | $24.2M | 156 | -16% | N/A | N/A |
#10 | $13.8M | 89 | 31% | N/A | N/A |
What Is Xpress Biologics?
Xpress Biologics is a biotech company proposing contract services for the production of recombinant proteins, antibody fragments and plasmid DNA for preclinical applications (therapeutic and diagnostic markets). The production scale goes from 100 mg up to 10 g with, depending of the use of the biologics, “R&D” and “GLP” qualities.The production processes proposed by Xpress Biologics are all developed in microbial expression system, E. coli (soluble cytoplasmic, inclusion bodies and periplasmic productions) and P. pastoris (secreted protein) mainly.These processes are IP free and take into account the regulatory and industrial (scale-up) requirements which facilitate the transfer of the project to CMOs (Contract Manufacturing Organizations) for the production of “GMP” grade material if necessary.Xpress Biologics acts as One-Stop-Shop and can, through project management with defined subcontractors, take in charge additional services as the screening and development of antibodies against specific targets, the production of “GMP” grade material, the organization of pre-clinical and clinical studies.
keywords:N/AN/A
Total Funding
67
Number of Employees
$10.4M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator